Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHM5GJ)

• Drug Name: 2-Methyl-2-Propanol Drug Info
• Synonyms: tert-Butanol; tert-Butyl alcohol; 2-Methyl-2-propanol; 2-Methylpropan-2-ol; 75-65-0; t-Butanol; t-Butyl hydroxide; 1,1-Dimethylethanol; Trimethylcarbinol; Trimethyl methanol; 2-Propanol, 2-methyl-; Tertiary-Butyl Alcohol; T-BUTYL ALCOHOL; Trimethylmethanol; tert-butylalcohol; Butanol tertiaire; Trimethyl carbinol; Dimethylethanol; tertiary-Butanol; Alcool butylique tertiaire; Methanol, trimethyl-; Arconol; tertiary Butyl Alcohol; tert.-butanol; tert- butyl alcohol; Caswell No. 124A; t-butylalcohol; tertiary butanol; NCI-C55367; tBuOH

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6386
  ChEBI ID: CHEBI:45895
  CAS Number: CAS 75-65-0
  TTD Drug ID: DMHM5GJ

Molecule-Related Drug Atlas

Drug(s) Targeting Calmodulin (CALM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halofantrine	DMOMK1V	Malaria	1F40-1F45	Approved	[3]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[4]
Aprindine	DMBXWU8	Cardiac arrhythmias	BC9Z	Approved	[5]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
MYRISTIC ACID	DMYX0BL	Discovery agent	N.A.	Investigative	[6]
Cacodylate Ion	DMK4XLD	Discovery agent	N.A.	Investigative	[1]
N-Trimethyllysine	DMZQXLS	Discovery agent	N.A.	Investigative	[1]
Calmidazolium	DM5ZTJL	Huntington disease	8A01.10	Investigative	[7]

Drug(s) Targeting Methionine aminopeptidase 2 (METAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beloranib	DM71CK8	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
D-Methionine	DMMKGBP	N. A.	N. A.	Phase 3	[1]
ZGN-1061	DM9KB7A	Type 2 diabetes	5A11	Phase 2	[9]
M8891	DMZ9NVP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
SDX-7320	DMU0Q6L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
PPI-2458	DMSAQBC	Autoimmune diabetes	5A10	Phase 1	[11]
TNP-470	DMT0QK8	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[12]
2-(phenylsulfonamido)-5-propylbenzoic acid	DMDGAHO	Discovery agent	N.A.	Investigative	[13]
5-p-Tolyl-1H-[1,2,3]triazole	DM2W0AD	Discovery agent	N.A.	Investigative	[14]
A-357300	DMZHDWN	Discovery agent	N.A.	Investigative	[12]

Drug(s) Affected By Somatotropin (GH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[2]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[15]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[16]
Cyproheptadine	DM92AH3	Allergic rhinitis	CA08.0	Approved	[17]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Sodium oxybate	DMBOV5P	Narcolepsy	7A20	Approved	[19]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[2]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[20]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[21]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calmodulin (CALM)	TTV3NH6	CALM1_HUMAN; CALM2_HUMAN; CALM3_HUMAN	Inhibitor	[1]
Methionine aminopeptidase 2 (METAP2)	TTZL0OI	MAP2_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Somatotropin (GH1)	OT92RTRD	SOMA_HUMAN	Protein Interaction/Cellular Processes	[2]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Metal-catalyzed oxidation of human growth hormone: modulation by solvent-induced changes of protein conformation. J Pharm Sci. 2001 Jan;90(1):58-69. doi: 10.1002/1520-6017(200101)90:1<58::aid-jps7>3.0.co;2-w.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
• [5] Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6.
• [6] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [7] Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135.
• [8] 2011 Pipeline of Zafgen.
• [9] The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1215-1219.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26.
• [12] Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15;63(22):7861-9.
• [13] Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
• [14] 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J Med Chem. 2005 Sep 8;48(18):5644-7.
• [15] Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine. Clin Pharmacol Ther. 1989 Jul;46(1):103-9. doi: 10.1038/clpt.1989.113.
• [16] Phosphatidylinositol 4-OH kinase is a downstream target of neuronal calcium sensor-1 in enhancing exocytosis in neuroendocrine cells. J Biol Chem. 2003 Feb 21;278(8):6075-84. doi: 10.1074/jbc.M204702200. Epub 2002 Dec 5.
• [17] [Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)]. Monatsschr Kinderheilkd (1902). 1978 Mar;126(3):123-6.
• [18] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [19] Failure of gammahydroxy butyric acid to stimulate growth hormone secretion in cocaine addicts. Neuropeptides. 1997 Oct;31(5):459-62. doi: 10.1016/s0143-4179(97)90040-8.
• [20] Effect of centrally acting alpha-adrenergic agonists on sympathetic nervous system function in humans. Hypertension. 1984 Sep-Oct;6(5 Pt 2):II57-62. doi: 10.1161/01.hyp.6.5_pt_2.ii57.
• [21] Thyrotropin-releasing hormone-induced GH release after cocaine withdrawal in cocaine addicts. Neuropeptides. 1999 Dec;33(6):522-5. doi: 10.1054/npep.1999.0773.
• [22] Effects of cortisol and cocaine on plasma prolactin and growth hormone levels in cocaine-dependent volunteers. Addict Behav. 2005 May;30(4):859-64. doi: 10.1016/j.addbeh.2004.08.019.